| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Dupilumab biosimilar (Jingxing Pharmaceutical) | GS101; GS-101; GS-101 (Jingxing Pharmaceutical) | Phase 3 Clinical | Jiangsu Jingxing Pharmaceutical Technology Co Ltd | Dermatitis, Atopic | Details |
| Dupilumab biosimilar (Qilu Pharma) | QL2108; QL-2108 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Asthma; Dermatitis, Atopic; Prurigo | Details |
| Tilrekimig | PF-07275315 | Phase 3 Clinical | Pfizer Inc | Asthma; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive | Details |
| Eblasakimab | MK-6105; ASLAN-004; CSL-334 | Phase 2 Clinical | Csl Ltd, Merck Sharp & Dohme Corp | Dermatitis, Atopic; Hypersensitivity | Details |
| Dectrekumab/VAK-694 | QBX-258 | Phase 2 Clinical | Novartis Pharma Ag | Asthma; Lymphedema | Details |
| OCH-NCNP1 | OCH-NCNP1 | Phase 2 Clinical | Keio University | Crohn Disease; Multiple Sclerosis | Details |
| Ompekimig | PF-07264660 | Phase 2 Clinical | Pfizer Inc | Dermatitis, Atopic | Details |
| AUP1602-C | AUP-16; AUP1602-C | Phase 2 Clinical | Aurealis | Diabetic Foot; Ulcer | Details |
| Dupixent biosimilar (Chong Kun Dang Pharmaceutical) | CKD-706 | Phase 1 Clinical | Chong Kun Dang Pharmaceutical Corp | Dermatitis, Atopic | Details |
| Dupilumab biosimilar (China Resources Biopharma) | Phase 1 Clinical | China Resources Biopharmaceutical Co Ltd | Dermatitis, Atopic | Details | |
| Dupilumab biosimilar (Jiangsu Jingxing Pharma) | Phase 1 Clinical | Jiangsu Jingxing Pharmaceutical Technology Co Ltd | Dermatitis, Atopic | Details | |
| Dupilumab biosimilar (Chengdu Kanghong) | KH-816; KH816 | Phase 1 Clinical | Chengdu Kanghong Biotechnologies Co Ltd | Dermatitis, Atopic | Details |
| Dupilumab biosimilar (Jushi Biopharma) | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Dermatitis, Atopic | Details | |
| Dupilumab biosimilar (Bio-Thera Solutions) | BAT2406; BAT-2406 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Asthma; Dermatitis, Atopic; Eosinophilic Esophagitis; Nasal Polyps; Prurigo Nodularis; Sinusitis | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Dupilumab | REGN-668; SAR-231893 | Approved | Regeneron Pharmaceuticals Inc, Sanofi | Dupixent, 达必妥 | United States | Dermatitis, Atopic | Regeneron Pharmaceuticals Inc | 2017-03-28 | Allergic Fungal Rhinosinusitis; Alopecia Areata; Angioedema; Aspergillosis, Allergic Bronchopulmonary; Asthma; Asthma, Aspirin-Induced; Chronic Urticaria; Colitis, Ulcerative; Conjunctivitis, Allergic; Coronavirus Disease 2019 (COVID-19); Dermatitis; Dermatitis, Atopic; Eczema; Eosinophilic Esophagitis; Eosinophilic gastroenteritis (EG); Genetic Diseases, Inborn; Hypereosinophilic Syndrome; Hypersensitivity; Hypersensitivity, Immediate; Keloid; Keratoconjunctivitis; Lichenoid Eruptions; Milk Hypersensitivity; Nasal Polyps; Nephrotic Syndrome; Neurodermatitis; Paranasal Sinus Diseases; Peanut Hypersensitivity; Pemphigoid, Bullous; Prostatic Neoplasms; Prurigo; Prurigo Nodularis; Pruritus; Pulmonary Disease, Chronic Obstructive; Respiration Disorders; Respiratory Sounds; Respiratory Tract Diseases; Rhinitis, Allergic; Scleroderma, Localized; Sinusitis; Skin Diseases; Skin Diseases, Eczematous; Sleep Apnea Syndromes; Urticaria | Details |
| Berdazimer sodium | NVN-1000-SB-206-Novan; SB-206; MAP3-NONOate - SB-206; NVN1000-SB206; SB-019; NI-MC101; SB-207; SB-208; SB-204; SB-414 | Approved | University Of North Carolina At Chapel Hill | KINSOLUSTM, Zelsuvmi, ZELSUVMI | United States | Molluscum Contagiosum | Lnhc Inc | 2024-01-05 | Acne Vulgaris; Condylomata Acuminata; Dermatitis, Atopic; Molluscum Contagiosum; Psoriasis; Tinea Pedis | Details |
